CVAC - Earnings announcements

Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter€400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to €551 million; expected cash runway re-affirmed into 2028CVGBM Phase 1 glioblastoma study showed 77% of patients with antigen-specific T-cell responses; data presented at ESMO, SITC and SNONew off-the-shelf program for squamous non-small cell lung cancer started, expected to enter Phase 1 in H2 2025New preclinical prophylactic vaccine program for urinary tract infections initiated, supported by positive preclinical data versus protein-based vaccinesPositive Phase 2 data from seasonal influen

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the third quarter and first nine months 2024 on Tuesday, November 12, 2024. The company will host a conference call and webcast on the same day at3 p.m. CET / 9 a.m. EST.Dial-in numbers to participate in the conference call:U.S. Toll-Free: +1-877-407-0989International: +1-201-389-0921Germany: 0800-182-0040 (landline access) / 0800-184-4713 (cell phone access)The live webcast link can be accesse

Closed new licensing agreement with GSK worth up to €1.45 billion, including €400 million upfront; provides strong validation of CureVac's mRNA platformInitiated strategic workforce reduction of ~30% by end of 2024, optimizing business to focus on high-value opportunities in oncology, infectious diseases and other areasInvoiced €10 million milestone payment after Phase 2 transition of pre-pandemic avian influenza (H5N1) program; candidate fully licensed to GSK under new agreementDosing of first patient in Phase 1 study Part B in glioblastoma with CVGBM to establish dose-confirmation; initial dose-escalation Part A data accepted for oral presentation at ESMOStrengthening of Supervisory Board

Organizational redesign on track, trimming residual pandemic infrastructure and reducing 150 positions by year endU.S. FDA Fast Track designation granted for pre-pandemic avian influenza (H5N1) vaccine currently in Phase 1 development; candidate jointly developed with GSKSettlement with Acuitas Therapeutics includes acknowledgment of CureVac's ownership of certain patent claims and Acuitas's licenses to selected patentsContinuation of U.S. patent litigation against Pfizer/BioNTech with trial expected to begin in Q2 2025; litigation continues under seven U.S. patents with three patents to be withdrawn due to out-licensing to Acuitas TherapeuticsProgress in German patent litigation against Pfi

Organizational redesign and rightsizing initiated across company to streamline structures, increase efficiency and reduce operating costsTogether with GSK, ended Pandemic Preparedness Agreement (PPA) with Federal Republic of Germany, after consultation with the German Federal Ministry of Health Cash and cash equivalents position of €402.5 million as of December 31, 2023; cash runway extended into Q4 2025 with organizational redesign and despite PPA wind-downStrategic collaboration signed with world-leading oncology center MD Anderson, creating unique expertise to jointly discover and develop novel cancer vaccinesAppointment of Thaminda Ramanayake as Chief Business Officer, bringing more than

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business UpdateEnrollment completed for Phase 2 COVID-19 study with mono- and bivalent vaccine candidates; study on track for data read-out in early 2024First participant dosed in seasonal flu Phase 2 study with potentially differentiated multivalent candidate; €15 million milestone payment by GSK triggeredPhase 1 study in glioblastoma well on track with opening of third dose level for CVGBM, CureVac's multiepitope cancer vaccine candidatePreclinical data with multiepitope construct in oncology shows strong T cells responses and significantly extended survival in checkpoint-inhibitor resistan

Initiated Phase 2 study in COVID-19 with monovalent and bivalent, modified mRNA vaccine candidates; continued execution on infectious disease development program in collaboration with GSKInitiated Phase 1 study of cancer vaccine candidate, CVGBM, for surgically resected glioblastoma; recruitment of second dose cohort well on trackBroadened position in patent litigations by expanding the scope and asserting new intellectual property rights in Germany and the U.S.Public hearing held before the Regional Court Düsseldorf as part of German patent litigation against Pfizer/BioNTechCash and cash equivalents position of €537.9 million as of June 30, 2023TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE

Continued technology platform validation with extended preliminary data from older adults in ongoing Phase 1 studies in COVID-19 and fluCOVID-19: monovalent modified mRNA construct CV0501 successfully boosted antibody titers against BA.1 and ancestral variants in adults age ≥65Flu: monovalent modified mRNA construct Flu-SV-mRNA elicited antibodies approximately 2.3 times those of licensed vaccine comparator in adults aged 60-80Reaffirming plan to advance modified mRNA COVID-19 and flu candidates to the next stages of clinical development in collaboration with GSK in 2023TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / January 30, 2023 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical c

Promising COVID-19 and flu modified mRNA vaccine candidates identified based on positive preliminary data from ongoing Phase 1 studiesAll candidates use CureVac's advanced second-generation mRNA backbone optimized to achieve improved mRNA translation and strong immune responses at low dosesThe preliminary results provide strong evidence of technology for CureVac's mRNA platform; CureVac and partner GSK plan to advance modified mRNA COVID-19 and flu candidates to the next stages of clinical developmentCOVID-19: monovalent modified mRNA vaccine candidate CV0501, encoding Omicron variant BA.1, successfully boosted antibody titers against BA.1 and the wild type variants and was generally well to

Delivering on broad second-generation vaccine development program with expansion into modified mRNA technology in collaboration with GSKPhase 1 studies in influenza and COVID-19 on track to deliver clinical data in Q1 2023Strengthening oncology position based on preparations for new clinical studies with mRNA-based cancer vaccine candidates and positive Phase 1 data on CV8102Two proof-of-principle studies planned in 2023 to validate and optimize second-generation mRNA backbone in oncologyPhase 1 expansion study of non-coding RNA-based candidate CV8102 confirms safety and strong immuno-modulatory characteristicsFirst manufacturing licenses for The RNA Printer® in oncology expected, subject to

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 10, 2022 / CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the third quarter of 2022 on Wednesday, November 16, 2022. The company will host a conference call and webcast on the same day at 3 p.m. CET / 9 a.m. ET.Conference call and webcast detailsDial-in numbers to participate in the conference call:U.S. Toll-Free: +1-877-407-0989International: +1-201-389-0921Germany: 0800 182 0040The live webcast link can be accessed via the newsroom section of the CureVac website at h

Delivering on broad 2022 second-generation vaccine development program with expansion into modified mRNA technology in collaboration with GSK; new candidates in COVID-19 and influenza enter clinical studiesPhase 1 initiated for modified COVID-19 vaccine candidate CV0501, targeting Omicron variantPhase 1 initiated for modified influenza vaccine candidate FLU SV mRNAAccelerating oncology strategy with complementary technology platforms and strong leadership supportAcquisition of Frame Cancer Therapeutics adds advanced genomics and bioinformatics capabilities to feed pipeline of cancer vaccine candidatesAppointment of Dr. Myriam Mendila, M.D., as Chief Development Officer adds international exp